Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Phase 1
20
about 4.3 years
18+
1 site in OR
About this study
This trial is testing a treatment with venetoclax, dasatinib, prednisone, rituximab, and blinatumomab in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) that is newly diagnosed or has returned. The goal is to determine if this combination can effectively treat these types of leukemia.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Blinatumomab
- 2.Receive Rituximab
- 3.Take Dasatinib
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
blinatumomab, dasatinib, methotrexate, prednisone, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), venetoclax
injection, intravenous, oral (Oral Tablet), oral, infusion
Primary: Incidence of adverse events, Incidence of dose-limiting toxicities
Secondary: Overall survival, Progression-free survival
biopsy, diagnostic
Oncology